Bharat Biotech this week offered Brazil a COVID-19 vaccine in advanced clinical trials and a possible technology transfer partnership, a company executive said on Friday.
The private Hyderabad-based pharmaceutical company is developing an inactivated whole virion vaccine called Covaxin which could be licensed by the second quarter of 2021.
“The data looks really good in terms of disease reduction and prevention, and we started our Phase 3 clinical trials this week,” Executive Director Sai Prasad told Reuters.
Bharat Biotech is currently recruiting 26,000 volunteers in India for the trials and the results are expected between March and April, he said.
Pfizer Inc said on Wednesday that it had offered to deliver millions of doses of its COVID-19 vaccine to Brazil during the first half of 2021, as the coronavirus spreads faster in South America’s largest country.
Pfizer and its German partner BioNTech SE reported the final results of trials which showed the vaccine to be 95% effective in preventing COVID-19.
Representatives from Bharat Biotech met this week with officials from the Brazilian health ministry and regulatory agency to see what the requirements are for the vaccine to be licensed in Brazil and whether trials should be done there as well.
“We are definitely open to partnerships and technology transfers,” Mr. Prasad said in an interview in Hyderabad.
Bharat Biotech has sold a hepatitis B vaccine in Brazil and is developing others for Zika and Chicungunya that are of interest to the South American country, he said.